Report overview
Many retinal biologics have been approved by the Food and Drug Administration (FDA), the European Medicine Agency (EMA) and the China Food and Drug Administration (CFDA) for the treatment of retinal diseases. Advancements in technologies and new mechanism of action for different biologics to treat retinal diseases are anticipated to boost the retinal biologics market.
This report aims to provide a comprehensive presentation of the global market for Retinal Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Retinal Biologics. This report contains market size and forecasts of Retinal Biologics in global, including the following market information:
Global Retinal Biologics Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The global Retinal Biologics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Macular Degeneration Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Retinal Biologics include Spark Therapeutics, Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc, AbbVie Inc, Johnson & Johnson Services, Inc and Amgen Inc, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Retinal Biologics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Retinal Biologics Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Retinal Biologics Market Segment Percentages, by Type, 2022 (%)
Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Uveitis
Others
Global Retinal Biologics Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Retinal Biologics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Retinal Biologics Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Retinal Biologics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Retinal Biologics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Retinal Biologics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Spark Therapeutics, Inc
F. Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals, Inc
AbbVie Inc
Johnson & Johnson Services, Inc
Amgen Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Retinal Biologics, market overview.
Chapter 2: Global Retinal Biologics market size in revenue.
Chapter 3: Detailed analysis of Retinal Biologics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Retinal Biologics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
